Treatment of chemical diabetes mellitus with sulfonylurea compounds by Fajans, Stefan S.
Treatment of Chemical Diabetes Mellitus 
With Sulf onylurea Compounds 
By Stefan S. Fajans 
Abnormality in glucose tolerance ap- 
pears to correlate with arteriosclerotic 
disease, even when the abnormality 
is quite mild. Though there is no evi- 
dence for prevention of these vascular 
problems by correction of the carbo- 
hydrate abnormality, it seems reason- 
able to attempt such a correction in 
an investigational setting. We have 
used sulfonylurea (tolbutamide, chlor- 
propamide) in children and young 
adults (935 yr) without obesity, who 
have chemical diabetes. No apparent 
effect on insulin output has been 
noted, even with normalization of glu- 
cose tolerance. 
B EFORE DISCUSSING the use of sulfonylurea compounds in the treatment of chemical diabetes, we must ask ourselves whether there is any evidence 
to indicate that mild carbohydrate intolerance may be harmful. Although this 
is a controversial question, there is some evidence that this may be true. There 
are four studies which give epidemiologic evidence. One is the Tecumsah, 
Michigan study. Dr. Ostrander, Dr. Epstein, and colleagues have shown that 
there is an excellent correlation between elevated blood sugar levels and the 
prevalence of coronary artery disease and generally of arteriosclerotic vascular 
disease.l*” This does not establish a cause and effect relationship necessarily, 
but it does establish a very strong correlation. Another epidemiologic study is 
the Bedford study, published by Keen et a1.3*4 Individuals with chemical 
diabetes as well as those with what was termed “borderline diabetes” were 
compared with control subjects. “Borderline diabetics,” by this definition, are 
individuals who had venous whole blood sugar levels between 120 and 
200 mg/100 ml 2 hr after a 50-g carbohydrate load. In these groups there 
was a correlation between blood sugar levels and the incidence of arterial 
disease. In addition to epidemiologic studies, there are studies of patients with 
arteriosclerotic heart disease. One study involved patients (mean age 46 yr) 
with coronary artery disease established by angiography.5 Abnormality of 
carbohydrate tolerance was found in 64% of those patients; abnormal lipid 
levels existed in about 51% of those patients. 6 Combining both sets of observa- 
tions, about 85% of all the patients with coronary heart disease had one or 
the other of these metabolic abnormalities. In another study of patients with 
coronary artery disease established by coronary arteriography, there was a 
63% incidence of an abnormality of glucose tolerance, while 74% of the 
patients had an elevation of serum lipids. 7 Abnormalities of carbohydrate 
or lipid metabolism were found in 91% of the patients. 
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Our own studies are anecdotal, but we have been impressed that, in families 
with arteriosclerotic vascular disease and diabetes, one observes the early 
appearance of coronary artery disease. We have the impression that many of 
the patients who develop coronary artery disease in middle age may have had 
some carbohydrate intolerance for many years. There is also some experi- 
mental evidence of a correlation between hyperglycemia and polyol formation 
in the aorta.’ Putting all these things together, it is my feeling that carbo- 
hydrate intolerance and hypoinsulinemia probably do lead to vascular damage. 
The internist sees patients with diabetes, be it mild or more severe, with 
cardiovascular disease, retinopathy, nephropathy, and with neuropathy. The 
pediatrician usually does not see these complications of diabetes. He is not as 
impressed with how mild the glucose intolerance can be in patients with these 
complications. Thus, it is easy to understand that the internist has been more 
concerned with prophylaxis than the pediatrician. 
Nobody has data indicating that correction of carbohydrate intolerance in 
young individuals will prevent the occurrence of these complications; never- 
theless, since these correlations exist in the adult it is reasonable to make an 
attempt to study this in the young. After all, we are not talking about estab- 
lished therapy, but we are discussing approaches to investigation. The 
investigative approaches do not imply that we recommend these procedures 
to every practicing physician in the country. We should make a very clear 
differentiation between investigative work and recommendations of what 
should be routine management. 
Our interest in using sulfonylureas in chemical diabetes stems from a 
concept which prevailed in the 19505, which I now believe to be incorrect. 
At that time it was thought that the course of diabetes in the young is 
normally one of rapid progression. In the early I~SOS, in young adult individ- 
uals with carbohydrate intolerance that did not improve on diet alone, we used 
small doses of insulin in the hope of preventing the progression of diabetes. 
The sulfonylureas became available for investigation in 195.5. I initiated 
sulfonylurea therapy in the first patient with chemical diabetes mellitus in 19.57 
when tolbutamide had become available generally for treatment of diabetes 
mellitus. This was a patient, aged 35, who on repeated tests had had progres- 
sion of carbohydrate intolerance. His tests reverted to normal after 4 mo of 
therapy with tolbutamide. At that time the reason for using a sulfonylurea 
was not simply the greater convenience than using 10 or 15 U of insulin. 
It was suspected, although not documented until the immunoassay for insulin 
became available, that one of the mechanisms of action of sulfonylureas was 
the increased secretion of insulin. As a result of the work of Loubatikes with 
dogs, it was also thought that the use of the sulfonylureas might cause hyper- 
trophy of the beta cells. Thus, we thought that we might be promoting an 
increase in beta-cell mass in these individuals. According to information we 
have published in the past, in a considerable number of individuals who were 
between the ages of 9 and 3.5 yr at diagnosis, we did have a certain amount 
of success in improving carbohydrate tolerance with the use of sulfony- 
Iureas.‘-” Later, with the availability of immunoassays for insulin, we did not 
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find improvement in the insulin response to glucose. However, there may be 
an increased effectiveness of circulating insulin, since blood glucose concen- 
trations are lower. Although I have great reservations about applying insulin/ 
glucose ratios to individual cases, it may be useful in evaluating the response 
to therapy of groups of individuals. 
I still think that sulfonylureas have something to offer in improving carbo- 
hydrate tolerance in chemical diabetes. However, I am not as sure today 
as I was 5 yr ago, because we have learned more about the natural history 
of the disease. When we administered tolbutamide to the first patient with 
chemical diabetes 13 yr ago, my concept was that we were dealing with a 
rapidly progressive disease. It is now clear that this is frequently not the 
case when we establish the diagnosis of asymptomatic diabetes.12 
As I discussed earlier, on successive glucose tolerance tests, whether looking 
at levels of blood glucose or plasma insulin, there may be marked fluctuations. 
It is unwise to draw any conclusions on the basis of a few glucose tolerance 
tests done before and after sulfonylurea therapy. Sequential testing is essential 
in order to develop reliable observations. 
Despite variability in the course of chemical diabetes in the young, I am 
still under the impression that in some patients the sulfonylureas have a favor- 
able effect on carbohydrate tolerance. In our studies, some of the patients 
that we switched to sulfonylureas had been on diet or diet plus insulin for 
5 yr. Each of these patients served as his own control. In the last IO yr, I 
have started a patient on a sulfonylurea only when he had at least four glucose 
tolerance tests at 3-mo intervals in which either no improvement on diet or 
progressive intolerance on diet alone had been shown. Thus, in each patient, 
we have established that there is not spontaneous fluctuation or improvement 
in carbohydrate tolerance prior to initiation of sulfonylurea therapy. 
We perform glucose tolerance tests with the patient taking the sulfonylurea 
until the night before, and then we do the second glucose tolerance test after 
2 days off tolbutamide or 2 wk off chlorpropamide. The classification of the 
status of each group is not on the basis of a single test but on the basis of 
multiple tests. All of these patients, of course, are nonobese. We have not 
administered these agents to any obese children or young adults; they are 
managed with diet alone. 
In summary, our results with sulfonylurea therapy are as reported pre- 
viously: There is a group that has shown no improvement, a few of whom 
have gone on to insulin requirement; there is a group that has shown a 
definite improvement in carbohydrate tolerance; and there is a small group 
that actually has had complete normalization of carbohydrate tolerance. 
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